Answers are grounded in this paper and cite their sources.
Analysis compares IMDC, MSKCC, and CFF risk models for determining treatment in metastatic renal cell carcinoma, indicating their effectiveness.
The aim of this study is to reveal the relationship and correlation between the International metastatic renal cell carcinoma (mRCC) Database Consortium (IMDC) and Memorial Sloan Kettering Cancer Center (MSKCC) risk models used to determine first-line treatment in metastatic mRCC and, less commonly, the Cleveland Clinic Foundation (CCF) prognostic risk model.
No takes yet. Share an insight, caveat, or question.
Keskinkılıç et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: